33. B-Cell Depleting Therapies and COVID-19
ACR on Air
00:00
The Risks of B Cell Depleting Therapies for COVID
Once the message was out there that B cell depleting therapies may place patients at increased risk of poor COVID outcomes, did you change your clinical practice in prescribing these drugs? You know, I love me some B cell depletion. And we use a lot of retuxanab in my lupus patients. We have a predominantly black population here in St. Louis and it seems to work just wonderfully for the vast majority of them. Of course, the most dangerous situation is not knowing what you don't know.
Transcript
Play full episode
